Patents Examined by Tracy Vivlemore
  • Pharmaceutical compounds
    Patent number: 11053213
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 6, 2021
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Peter Hewitt, Mary Melissa McFarland, James Samuel Shane Rountree, Frank Burkamp, Christina Bell, Lauren Proctor, Matthew Duncan Helm, Colin O'Dowd, Timothy Harrison
  • Methods for treating hepatitis B infection
    Patent number: 11052105
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Nanodiamond particles and related devices and methods
    Patent number: 11047851
    Abstract: Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the device comprises a plurality of nanodiamond particles and a species bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 29, 2021
    Assignee: Debina Diagnostics, Inc.
    Inventors: Giora Z. Feuerstein, Mark E. Sternberg
  • Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
    Patent number: 11046657
    Abstract: A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 29, 2021
    Assignees: Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg, Universite Paris-Sud, Centre International de Recherche aux Frontieres de la Chimie
    Inventors: Dominique Bonnet, Nelly Frossard, Jean-Luc Galzi, Christophe Guignabert, Marcel Hibert, Frédéric Simonin, Sylviane Muller
  • Antisense oligonucleotides that inhibit influenza virus replication and uses thereof
    Patent number: 11046958
    Abstract: Antisense oligonucleotides (ASOs) that disrupt RNA-RNA interactions of influenza virus genome segments that are required for virus packaging are described. The ASOs can be used to inhibit influenza A virus replication in vitro and in vivo. Use of the ASOs for the treatment of a subject with an influenza virus infection is also described.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 29, 2021
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Seema S. Lakdawala, Nara Lee
  • Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof
    Patent number: 11040977
    Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 22, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benno Rothenhaeusler, Rene Trussardi, Fabienne Hoffmann-Emery, Urs Schwitter, Jean-Michel Adam, Olaf Grassmann, Thomas Hartung, Frederic Ran, Ralph Diodone, Christophe Pfleger, Bjorn Bartels
  • Conjugates of kinase inhibitors and cyanine dyes
    Patent number: 11040106
    Abstract: The present disclosure provides conjugates of kinase inhibitors and cyanine dyes, as well as related compositions, methods and uses.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: June 22, 2021
    Assignee: Small Molecule PPI Mimics LLC
    Inventors: Kevin Burgess, Syed Muhammad Usama
  • Pharmaceutical composition for preventing or treating hepatitis B
    Patent number: 11033571
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing hepatitis B, comprising: at least one oligonucleotide selected from the group consisting an oligonucleotide represented by a nucleic acid sequence of SEQ ID NO: 1, 2, or 6 or a nucleic acid sequence complementary thereto; and an oligonucleotide having at least one chemical modification on the oligonucleotide, as an active ingredient, and a method for screening a therapeutic agent for hepatitis B according to the formation of a G-quadruplex by HBV and a candidate material. The pharmaceutical composition forms a G-quadruplex with HBV and reduces cccDNA (covalently closed circular DNA) and thus can be used in the treatment or prevention of hepatitis B.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 15, 2021
    Assignee: AM SCIENCES INC
    Inventors: Kyun Hwan Kim, Doo Hyun Kim, Yeong Min Park
  • Platinum-resistant cancer treatment
    Patent number: 11026948
    Abstract: A compound of formula I or a pharmaceutically acceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between 1 mg/m2 and 30 mg/m2 of compound per patient body surface area per administration. Method of treatment and novel dosage forms are also provided. Particularly treated arc ovarian cancers, particularly those expressing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: June 8, 2021
    Assignee: BTG INTERNATIONAL LIMITED
    Inventor: Udai Banerji
  • Compounds and methods for reducing FXI expression
    Patent number: 11021710
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition without a significant increase in a bleeding risk. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, death of tissue, and death.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 1, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Huynh-Hoa Bui
  • Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
    Patent number: 11021707
    Abstract: The present disclosure relates to RNAi constructs with improved cellular uptake characteristics and methods of use of these compounds for silencing expression of long coding RNAs (IncRNAs).
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: June 1, 2021
    Assignees: Phio Pharmaceuticals Corp., Biogazelle NV
    Inventors: James Cardia, Karen G. Bulock, Joke Hedwig Vandesompele, Gert Van Peer
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 11021475
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski
  • DNA-PK inhibitors
    Patent number: 11021465
    Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 1, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul S. Charifson, Kevin Michael Cottrell, Hongbo Deng, John P. Duffy, Huai Gao, Simon Giroux, Jeremy Green, Katrina Lee Jackson, Joseph M. Kennedy, David J. Lauffer, Mark Willem Ledeboer, Pan Li, John Patrick Maxwell, Mark A. Morris, Albert Charles Pierce, Nathan D. Waal, Jinwang Xu
  • Compositions and methods for treating cancer
    Patent number: 11013754
    Abstract: Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: May 25, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Arul Chinnaiyan, Rohit Malik, Yajia Zhang, Marcin Cieslik, Sethuramasundaram Pitchiaya
  • Oligonucleotides, compositions and methods thereof
    Patent number: 11013757
    Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 25, 2021
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Jason Jingxin Zhang, Naoki Iwamoto, Christopher J. Francis, Chandra Vargeese, David Charles Donnell Butler, Sethumadhavan Divakaramenon, Genliang Lu, Subramanian Marappan
  • Preparation of nanocrystals with mixtures of organic ligands
    Patent number: 11011603
    Abstract: Semiconductor nanocrystals prepared using a mixture of organic ligands (e.g., oxoacids), as well as compositions, kits, and methods of using such semiconductor nanocrystals are disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 18, 2021
    Assignee: Life Technologies Corporation
    Inventors: Joseph Bartel, Yongfen Chen, Noah Lermer, Timothy Carter, Scott Sweeney, Chad Teters, Wenxi Huang
  • DNA-PK inhibitors
    Patent number: 11008305
    Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 18, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Paul S. Charifson, Kevin Michael Cottrell, Hongbo Deng, John P. Duffy, Huai Gao, Simon Giroux, Jeremy Green, Katrina Lee Jackson, Joseph M. Kennedy, David J. Lauffer, Mark Willem Ledeboer, Pan Li, John Patrick Maxwell, Mark A. Morris, Albert Charles Pierce, Nathan D. Waal, Jinwang Xu
  • CCR7 aptamers and uses thereof
    Patent number: 11007211
    Abstract: Disclosed herein are CCR7 aptamers that specifically bind to and internalize into CCR7-expressing cells. The aptamers can be used as a therapeutic agent by itself or in combination with a small molecule by forming a conjugate with the small molecule. Targeted delivery of the small molecule can be achieved by such conjugates. Also disclosed are methods of treating a subject suffering from cancer by administering an effective amount of the aptamer or the aptamer-small molecule conjugate to the subject.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: May 18, 2021
    Assignee: CITY OF HOPE
    Inventors: John Rossi, Jiehua Zhou, Mayumi Takahashi
  • Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
    Patent number: 11008309
    Abstract: The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: May 18, 2021
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis, Dilara McCauley, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Chemically modified RNA aptamers and uses thereof
    Patent number: 11008576
    Abstract: Provided are chemically modified ribonucleic acid (RNA) aptamers comprising one or more of 2?F guanylate, 2?OMe cytidylate, 2?OMe adenylate, and a deoxy pyrimidine nucleotide with a moiety on the 5 position of the pyrimidine; and methods of making the aptamers.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: May 18, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Matthew Levy, Arijit Bhowmick